- Home
- ETON vs ERAS Comparison
ETON vs ERAS Comparison
Compare ETON & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- ERAS
- Stock Information
- Founded
- ETON 2017
- ERAS 2018
- Country
- ETON United States
- ERAS United States
- Employees
- ETON N/A
- ERAS N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- ETON Health Care
- ERAS Health Care
- Exchange
- ETON Nasdaq
- ERAS Nasdaq
- Market Cap
- ETON 388.3M
- ERAS 348.4M
- IPO Year
- ETON 2018
- ERAS 2021
- Fundamental
- Price
- ETON $14.85
- ERAS $1.45
- Analyst Decision
- ETON Strong Buy
- ERAS Strong Buy
- Analyst Count
- ETON 3
- ERAS 6
- Target Price
- ETON $29.67
- ERAS $4.83
- AVG Volume (30 Days)
- ETON 636.4K
- ERAS 1.2M
- Earning Date
- ETON 08-07-2025
- ERAS 08-11-2025
- Dividend Yield
- ETON N/A
- ERAS N/A
- EPS Growth
- ETON N/A
- ERAS N/A
- EPS
- ETON N/A
- ERAS N/A
- Revenue
- ETON $48,327,000.00
- ERAS N/A
- Revenue This Year
- ETON $103.21
- ERAS N/A
- Revenue Next Year
- ETON $51.34
- ERAS N/A
- P/E Ratio
- ETON N/A
- ERAS N/A
- Revenue Growth
- ETON 40.88
- ERAS N/A
- 52 Week Low
- ETON $3.25
- ERAS $1.01
- 52 Week High
- ETON $21.48
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- ETON 54.31
- ERAS 52.19
- Support Level
- ETON $13.78
- ERAS $1.38
- Resistance Level
- ETON $16.27
- ERAS $1.58
- Average True Range (ATR)
- ETON 0.83
- ERAS 0.11
- MACD
- ETON 0.32
- ERAS 0.01
- Stochastic Oscillator
- ETON 77.67
- ERAS 64.86
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.